Teppei Yamaguchi

7PUBLICATIONS
5CO-AUTHORS
Predictive and prognostic markersMolecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Innate immunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Apr 26, 2026
Five-year prognostic impact of pre-existing interstitial lung disease in non-small cell lung cancer patients treated with anti-PD-1 monotherapy: a retrospective analysis.

|Jul 15, 2024
Efficacy of chemotherapy plus immune checkpoint inhibitors in patients with non-small cell lung cancer who have rare oncogenic driver mutations: a retrospective analysis.

Teppei Yamaguchi, Junichi Shimizu, Reiko Matsuzawa

|Jun 17, 2024
Atezolizumab and nintedanib in patients with non-small cell lung cancer and interstitial lung disease.

Teppei Yamaguchi, Junichi Shimizu, Fumie Shigematsu

|Jan 25, 2024
First-line nivolumab plus ipilimumab with or without chemotherapy for Japanese patients with non-small cell lung cancer: LIGHT-NING study.

Hisao Imai, Takashi Kijima, Koichi Azuma

|Jan 19, 2022
Risk factors for pneumonitis in patients with non-small cell lung cancer treated with immune checkpoint inhibitors plus chemotherapy: A retrospective analysis.

Teppei Yamaguchi, Junichi Shimizu, Yuko Oya

|Aug 17, 2021
Pre-existing interstitial lung disease is associated with onset of nivolumab-induced pneumonitis in patients with solid tumors: a retrospective analysis.

Teppei Yamaguchi, Junichi Shimizu, Takaaki Hasegawa

Pageof 2

Frequent Collaborators

1 joint publications

Takaaki Hasegawa

1 joint publications

Hisao Imai

1 joint publications

Junko Tanizaki

1 joint publications

Hidehito Horinouchi